Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
Active, not recruiting · Phase 3 · NCT04656652
Conditions: Non-small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $379,206
- U.S. investigators named
- 17
- Sites paid
- 16
- Planned or actual enrollment
- 605
About the trial
- Sponsor
- Daiichi Sankyo (with AstraZeneca)
- Tested
- DS-1062a (drug), Docetaxel (drug)
- Dates
- Started 2020-12-21; completion 2027-02-15
- Results posted
- Yes
This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations.
From ClinicalTrials.gov, last updated 2026-08-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $379,206 in research payments for this study in 2025 (52 payments).
Products named: Datroway
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sujith R. Kalmadi, MD Hematology & Oncology · Chandler, AZ
- Aaron Lisberg, MD Hematology & Oncology · Santa Monica, CA
- Giribala R. Patel, M.D. Medical Oncology · Fullerton, CA
- Lisa S. Wang, M.D. Hematology & Oncology · Whittier, CA
- Marina Chiara Garassino, MD Medical Oncology · Chicago, IL
- Ahad A. Sadiq, M.D Hematology & Oncology · Fort Wayne, IN
- Jacob M. Sands, MD Hematology & Oncology · Burlington, MA
- Bruno S. Fang, MD Hematology & Oncology · East Brunswick, NJ
- Khawaja S. Jahangir, M.D. Hematology & Oncology · Las Vegas, NV
- Afshin Dowlati, MD Hematology & Oncology · Cleveland, OH
- Balazs Halmos, MD Hematology & Oncology · Cleveland, OH
- Benjamin M. Solomon, MD Hematology & Oncology · Sioux Falls, SD
- Melissa L. Johnson, MD Medical Oncology · Nashville, TN
- Ray Page, D.O. Hematology & Oncology · Weatherford, TX
- Stephan D. Kendall, M.D. Medical Oncology · Salt Lake City, UT
- Richard D. Hall JR., M.D. Medical Oncology · Charlottesville, VA
- Andrea L. Veatch, MD Hematology & Oncology · Puyallup, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Virginia Medical Center, VA $104,728
- Ronald Reagan UCLA Medical Center, CA $45,399
- Northwest Medical Specialties - Tacoma $40,224
- Urologic Health Associates $38,883
- Biomedical Research Alliance of New York LLC $35,795
- Dana-Farber Cancer Institute $33,215
- Titan Health PArtners Llc $27,781
- Sarah Cannon Research Institute $22,000
- Oncology Hematology Consultants, PA $10,034
- Translational Research in Oncology Us Inc $7,732
- University of Chicago $5,720
- Uh Cleveland Medical Center, OH $2,750
- Avera Mckennan Hospital & University Health Center, SD $1,500
- Oncology Hematology Consultants PA $1,300
- Iho Corporation $1,200
- Robert B Mcbeath MD PC $945
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.